
The EU Committee for Medicinal Products for Human Use (CHMP) has convened its monthly meeting, with a Danish treatment on the agenda.
The publicized agenda includes a point concerning a possible indication extension for Leo Pharma’s eczema treatment, tralokinumab, which is marketed in the EU as Adtralza and in the US as Adbry.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app